Alzheimer’s Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: March 01, 2021
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 4.68 billion |
|
Revenue Forecast in 2031 |
US$ 17.66 billion |
|
CAGR |
5.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Alzheimer's drugs market was valued at US$ 4.68 billion in 2022 and is expected to register a revenue CAGR of 5.5% to reach US$ 17.66 billion by 2031
Alzheimer's Market Fundamentals
Alzheimer's disease is a brain ailment that gradually impairs memory, cognitive skills, and the capacity to do even the most basic tasks. Symptoms of Alzheimer's disease usually show later in life in the majority of people. Alzheimer's disease is the seventh-largest cause of mortality in the United States and the primary cause of dementia in older persons. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to the point that they interfere with a person's everyday life and activities. Dementia progresses in intensity from the mildest stage, when it is just beginning to impede a person's functioning, to the most severe stage, when the individual must fully rely on others for assistance with basic daily activities.
Alzheimer's disease affects about 6 million Americans of all ages. In 2023, an estimated 6.7 million Americans aged 65 and over will have Alzheimer's disease. Seventy-three percent are 75 years old or older. Alzheimer's disease affects around one in every nine adults aged 65 and older (10.7%). Women account for about two-thirds of Alzheimer's patients in the United States.
The initial signs of Alzheimer's disease differ from person to person. Nonmemory components of cognition, such as word searching, vision/spatial difficulties, and poor thinking or judgment, may signify the very early stages of the disease for many people. Biomarkers (biological indicators of illness detected in brain imaging, cerebrospinal fluid, and blood) are being studied by researchers to detect early changes in the brains of persons with MCI and cognitively normal people at higher risk for Alzheimer's.
While Alzheimer's cannot be cured and its progression cannot be stopped, its progression can be slowed, and symptoms can be alleviated through therapies and medications. The goal of treatment is to reduce behavioral abnormalities while also improving overall patient well-being. A well-coordinated mix of treatment approaches in the early phases might greatly contribute to retaining patient independence and quality of life.
Aducanumab/AduhelmTM, Donepezil/Aricept®, Galantamine/Razadyne®, Rivastigmine/Exelon®, Memantine/Namenda®, and Memantine + Donepezil/Namzaric® are among the treatments available for the disorder. Suvorexant/Belsomra® is prescribed to treat non-cognitive (behavioral and psychological) problems.
[977345]
Alzheimer's Market Dynamics
The rising incidence of Alzheimer's disease worldwide is the primary factor boosting market expansion. For instance, the WHO announced in September 2022 that around 55 million people worldwide live with dementia, with nearly 10 million cases recorded annually. According to the WHO, Alzheimer's disease is the most prevalent kind of dementia, accounting for 60-70% of all dementia cases.
Transcranial Pulse Stimulation (TPS®) is a new contemporary treatment that has recently become accessible. TPS is used to treat individuals with mild to severe Alzheimer's disease to promote/maintain mental capacities. Acoustic pulses generated outside the body are injected specifically into the brain areas that require therapy; treatment is provided on an outpatient basis. Such developments are likely to boost the global market for Alzheimer's drugs. TPS is simple and safe, with an average treatment time of 30 minutes per session; one course of therapy consists of six sessions spread out over two weeks. TPS has had a lot of success.
In Alzheimer's disease, there has been an increase in the use of various machine learning approaches, most commonly with imaging data, for diagnosis and disease progression. This covers, among other things, amyloid PET imaging, combined PET and MR imaging, and spectrum phenotyping. Researchers from the VA Bedford and VA Boston healthcare systems, for example, devised a non-invasive optical approach that aids in the detection of Alzheimer's disease. This novel method uses spectroscopy to detect structural changes in the brain. This technical breakthrough has expected to meet the demands of persons living with dementia, informal carers, official caregivers, and social caregivers, creating a massive potential in the Alzheimer's drugs industry trends.
The pipeline drugs are rising throughout the projection period due to the upcoming introduction of various disease-modifying medications. Companies such as F. Hoffmann-La Roche Ltd., Biogen/Eisai Inc., and Eli Lilly and Company have developed therapeutic candidates to change the therapy landscape for Alzheimer's disease. According to the Alzheimer's Association, there were 143 medication candidates in 172 research studies for Alzheimer's disease. There are 31 therapeutic candidates in phase 3 clinical trials, 82 in phase 2, and 30 in phase 1.
Because of the unpredictability, failure, and abandonment of Alzheimer's medication research studies, just a few therapy options are available. This raises the expenses of R&D. As a result, it is projected to limit the market growth. For example, Amgen Inc. and Novartis AG halted their Phase 2 clinical study for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer's disease, in July 2019 due to a lack of anticipated results.
Alzheimer's Market Ecosystem
The global Alzheimer's drugs market is analyzed by drug class, end user, and region from the following perspectives.
Alzheimer's Drugs Market by Drug Class
[2132442]
Based on the drug class, the Alzheimer's drugs market is segmented into NMDA receptor antagonists, cholinesterase inhibitors, and others (combined drugs, monoclonal antibodies, etc.).
The NMDA receptor antagonists segment consists of the Memantine drug. Whereas cholinesterase inhibitors consist of Galantamine, Rivastigmine, and Donepezil drugs.
The cholinesterase inhibitors segment dominates the market with the largest revenue share. The segment’s revenue growth can be attributed to the wide usage of cholinesterase. Several pharmaceutical companies are developing Alzheimer's therapeutics based on cholinesterase inhibitors and are expected to grow the segment over the forecast period. For example, Corium, Inc. disclosed in October 2021 that the USFDA had set a PDUFA target action for Corium'sium's new drug application for once-weekly ADLARITY (donepezil transdermal syst) It is most typically a patch formulation of donepezil. This patch treats mild, moderate, or severe Alzheimer's disease dementia.
Alzheimer's Drugs Market by End User
Based on the distribution channels, the Alzheimer's drugs market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Increase in hospitalization due to an increase in the senior population and Alzheimer's patients, the hospital pharmacy segment dominated the market. According to the Alzheimer's Association Report 2022, there were 518 hospitalizations per 1,000 Medicare seniors with Alzheimer's or other dementias in the elderly population, compared to 234 hospitalizations per 1,000 Medicare beneficiaries without these illnesses. However, given the prevalence of Alzheimer's disease, the total number of hospitalizations for AD patients is expected to remain low.
Alzheimer's Drugs Market by Region
Based on region, the global Alzheimer's drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is predicted to increase significantly throughout the projection period because of the high prevalence of Alzheimer's disease and an aging population, as well as considerable investment in research & development activities and the introduction of new medicines. For instance, in a June 2021 interview, the Chief Science Officer of the Alzheimer's Society of Canada predicted that during the next ten years, more than one million Canadians will be living with dementia. This suggests that the rising incidence of Alzheimer's disease in the North American area is projected to enhance demand for Alzheimer's diagnostic and treatment solutions, thereby driving the market growth during the forecast period.
Furthermore, the region's aging population is expected to increase the burden of Alzheimer's disease. The geriatric population is more vulnerable to neurodegenerative diseases like Alzheimer's. For example, according to the Alzheimer's Association Report from March 2022, roughly 6.2 million individuals aged 65 and older in the United States have Alzheimer's-related dementia, which is expected to rise to 13.8 million by 2060.
The Asia Pacific area is predicted to be the fastest-growing region during the forecast period, owing to increased public awareness and research efforts to find innovative medications to treat Alzheimer's disease. Approximately 487,500 Australians will be living with dementia in 2022, which is anticipated to rise to 1.1 million by 2058. Dementia is Australia's second biggest cause of mortality.
Alzheimer's Competitive Landscape
New product releases and R&D spending are two main techniques used by significant businesses to get a larger market share. For example, Eisai/Biogen's anti-amyloid antibody, Aduhelm, was approved for treating Alzheimer's in June 2021. Another product, lecanemab, is also in the works for the firm. The FDA in the United States has accepted the BLA for lecanemab and is scheduled to make a decision on its approval by January 2023. Some of the prominent market players in the global Alzheimer's drugs include,
Alzheimer's Strategic Development
Alzheimer's disease is a brain ailment that gradually impairs memory, cognitive skills, and the capacity to do even the most basic tasks. Symptoms of Alzheimer's disease usually show later in life in the majority of people. Alzheimer's disease is the seventh-largest cause of mortality in the United States and the primary cause of dementia in older persons.
North America region is dominating the global Alzheimer's drugs market.
The estimated market size of the Alzheimer's drugs Market in 2031 will be 17.66 billion.
The revenue CAGR of the Alzheimer's drugs market during the forecast period will be 15.9%.
Some prominent market players in the global Alzheimer's drugs include Eisai Co., Ltd., F. Hoffmann La Roche Ltd., and Novartis AG.
*Insights on financial performance are subject to the availability of information in the public domain